• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Methods of screening,monitoring and management of cardiac toxicity induced by chemotherapeutics

    2022-07-11 03:38:28HumayraAfrinChristianelJosephSalazarMohsinKaziSyeRizwanAhamaMajeAlharbiNurunnabi
    Chinese Chemical Letters 2022年6期

    Humayra Afrin,Christianel Joseph Salazar,Mohsin Kazi,Sye Rizwan Ahama,Maje Alharbi,M Nurunnabi,e,f,?

    a Environmental Science &Engineering,University of Texas at El Paso,El Paso,TX 79965,United States

    b Border Biomedical Research Center,University of Texas at El Paso,El Paso,TX 79965,United States

    c Department of Pharmaceutics,College of Pharmacy,King Saud University,Riyadh 11451,Kingdom of Saudi Arabia

    d Central Laboratory,Department of Pharmaceutical Chemistry,College of Pharmacy,King Saud University,Riyadh 11451,Kingdom of Saudi Arabia

    e Department of Biomedical Engineering,University of Texas at El Paso,El Paso,TX 79965,United States

    f Department of Pharmaceutical Sciences,School of Pharmacy,University of Texas at El Paso,El Paso,TX 79902,United States

    Keywords:Cardiotoxicity Anticancer drug Chemotherapy Screening Biomarker

    ABSTRACT Cardiac toxicity is one of the most common side effects of anticancer drugs.Cardiac toxicity results dysfunction of heart including hypotension,heart failure,and even cause death in extreme cases.The potential risk of cardiotoxicity is a huge concern in chemotherapeutics mediated cancer treatment.The individual with any pre-existing cardiac issues are excluded from clinical trials due to the potential risk of cardiotoxicity.Because of the potential cardiotoxicity,there is an emerging need for alternatives of some very potent anticancer drugs (doxorubicin/DOX,5-fluorouracil/5FU,trastuzumab).While a patient is being treated with anticancer drugs,early blood screening,biomarker detection,and careful monitoring of cardiac functions are necessary to be able to avoid any irreversible cardiac damage.Therefore,early detection methodology to monitor cardiotoxicity in real-time,and a drug formulation that prevent interaction between drug and cardiac cell,seemingly have potential to mitigate the risk.In this review,we have summarized the cardiotoxicity of the most used anticancer drugs,their pathophysiology and some of the conventional and newer screening methods available to manage an individual patient in clinic.We have also incorporated our perspective on how a rationale designing of biomolecules can be used to overcome the cardiotoxicity generated chemotherapeutics.

    1.Introduction

    The human heart is one of the vital organs of the body.Heart pumps the blood throughout the body,supplies oxygen and nutrients to the tissues and removes carbon dioxide and other wastes.Heart is a four-chamber organ which includes many cell types including myocytes,endothelial cells,fibroblasts,and vascular smooth muscle cells.Each cell type play vital role in maintaining regular cardiac function [1].Cardiomyocyte cells are permanent cell that do not regenerate.Therefore,any damage to the cardiomyocytes negatively impact to the cardiac function.Antineoplastic agents have shown cardiac toxicity which is a rising concern among oncologists [2–4].According to the data collected by National Center for Health Statistics in 2018,in 2021,1898,160 new cancer patients will be diagnosed in United State and among them 608,570 patients will die [5].Incidence of cancer increases with the increased age and is more within 40?80 years of age [6].The risk of developing cardiac disease increases with the advanced age with or without exposure the of anticancer agents.It is a huge challenge for oncologists to continue the antineoplastic therapy with minimum or no cardiovascular side effect to minimize the cardiac dysfunction that may result fatality.

    Anticancer treatment modalities including chemotherapy,immunotherapy and radiotherapy involving cardiac structure causes cardiac complications [7].Anthracycline (DOX,epirubicin,idarubicin),HER-2 inhibitor (Trastuzumab),anti-VEGF therapy (tyrosine kinase inhibitor,imatinib,dasatinib,nilotinib,bosutinib,sunitinib,sorafenib,axitinib,ponatinib),and immunotherapy have shown cardiac side effects including heart failure (HF),cardiomyopathy,myocarditis,hypertension (HTN),decrease left ventricular ejection fraction (LVEF),atherosclerosis [2,8]as a short term or long term complication.A pre-and post-treatment systematic screening and monitoring for cardiac disease can help in early detection and improve quality of life of both cancer patients and survivors [8,9].Research is being carried out to develop an effective early diagnostic tool,better monitoring system and novel drug delivery system.A metanalysis on tyrosine kinase inhibitor (TKI) cardiotoxicity in 2018 stated that,the early awareness,initiation of appropriate management,and close monitoring can enhance the benefits of TKI therapy [10].

    Previously,there have been some extensive reviews published on cardiotoxic anticancer drug [11,12],screening and management[9].However,in this review we will discuss the available strategies and techniques for monitoring cardiac function utilizing biomarkers and modern imaging technologies.We will also discuss how early detection and better diagnosis can help physicians to develop an appropriate dose regimen to reduce the risk of irreversible cardiac damage.Finally,we will discuss the recent advancement in drug delivery science that has shown potential to minimize direct interaction between the anticancer drug and cardiac tissue as delineate the knowledge gap and possible future research direction.

    2.Cardiac complication from anticancer therapy

    2.1.Pathogenesis of cardiotoxicity

    Anticancer mediated cardiac myopathy has been classified into two categories.Type 1: A irreversible myocardial damage due to oxidative stress on cardiac myocyte,and mitochondrial dysfunction causing morphological changes which is caused by anthracyclines,mitoxantrone or cyclophosphamide.Type 2: A reversible cardiac damage caused by trastuzumab or tyrosine kinase inhibitors (TKIs)which blocks the ErbB2 pathway and interrupt growth,repair,and survival of cardiomyocytes without changing the morphology[13–16].

    Anthracycline (ATN) mediated cardiotoxicity is very much dose dependent.For example,2.2% of the patient receiving DOX results in heart failure (HF) at a cumulative dose of 300 ~<550 mg/m2and this incidence increases up to 26%?30% with total doses of 500–800 mg/m2[17].Heart failure related mortality rate among the patients dosed with DOX is in range of 27%?60% [18,19].Another study shows 4% patient develops HF receiving DOX at a dose of 500–550 mg/m2whereas dose of 600 mg/m2or more raises the risk to above 36% but epirubicin or idarubicin shows very low degree of HF incidence [20,21].The main cause of cardiac damage due to doxorubicin is inhibition of topoisomerase 2β(TOP2) and reactive oxygen species (ROS) [22–24].TOP2 is overexpressed in cardiomyocyte.Doxorubicin forms a complex with TOP2 and DNA.This complex causes DNA damage and leads to cell death [24–26].DOX stimulates the ROS/RNS (reactive nitrogen species) production and causes free radical injury (Fig.1) and causes DNA damage [27].Other factors for DOX induced cardiac damage includes mitochondrial iron accumulation,calcium overload in sarcoplasmic reticulum,impaired protein synthesis [27–31].Another study stated that doxorubicinol,DOX metabolite,is known to be responsible for cardiotoxicity.Doxorubicinol is also known to be more potent than DOX at inhibiting calcium channel [31,32]

    HER-2 is a protooncogene,one of the 4-member family (HER-1,HER-2/erbB2,HER-3,HER-4) of receptor tyrosine kinase,is highly expressed in 20%?30% of breast cancers [33]and associated with poor prognosis,increase chance of metastasis and drug resistance of breast cancer [34].In heart HER-2,HER-4/HER-4 homodimerization,and HER-4/HER-2 heterodimerization induce cell survival and activate protective pathways specially in cardiac stress (Fig.2)[35].Inhibition of neuregulin (which triggers dimerization) in heart causes impairment of HER-4/HER-4 homodimerization and HER-4/HER-2 heterodimerization on cardiomyocyte which leads to mitochondrial dysfunction mediated cell death [25,36,37].

    Fig.1.Anthracycline causes cardiac damage by inhibiting TOP2 (topoisomerase 2β),and by producing ROS (reactive oxygen species).TOP2 inhibition in cardiomyocyte causes DNA intercalation and damages myocardial DNA.Excessive production of ROS in mitochondria causes damage of mDNA (mitochondrial DNA).Intracellular accumulation of Ca and Fe also contributes the cardiotoxicity produced by DOX therapy.

    Fig.2.Trastuzumab promotes dimerization of HER-2 which is overexpressed in breast cancer and causes proliferation of cancer cell.HER-2 homodimerization and heterodimerization with HER-3 is inhibited by trastuzumab and halt the cancer cell growth (left side).On the other hand,trastuzumab inhibits the neuregulin which inhibits the protective dimerization of HER-2 and cardiomyocyte and causes mitochondrial dysfunction and cell death.Reproduced with permission from [30].Copyright 2018,Frontiers.

    Tyrosine kinase inhibitor (TKI) mediated mechanism of cardiotoxicity has reported earlier in elsewhere [36].Small moleculebased TKI has been shown to have cardiotoxicity like HF and left ventricular dysfunction (LVD) [37,38].Imatinib causes cardiotoxicity by activating Endoplasmic Reticulum (ER) stress response,decreasing the mitochondrial membrane potential,releasing cyt c into the cytoplasm,depleting ATP in cell and cell death[36,37].

    Several recently published review paper discussed on the mechanism of action of 5-flurouracil (5-FU) induced cardiotoxicity in detail [39,40].5-FU mediated cardiotoxicity induction mechanism involved thrombosis due to endothelial injury,and increased metabolism which leads to depletion of energy,ischemia,and cellular damage.5-FU also result oxidative stress,coronary spasm and reduction in the ability of transfer O2by red blood cells that lead to myocardial infarction [40].

    Immunotherapy is among the newest treatment modality for cancer that works as a revolutionary in poor prognostic cancer.Most importantly the immunotherapy considers as much safer therapeutic modality compared to the small molecule-based chemotherapeutics.Immune-check point inhibitors (ICI) such as avelumab,pembrolizumab,ipilimumab,and nivolumab causes autoimmune cardiotoxicity [41].Result from a preclinical trial shows programmed cell death 1 (PD 1) and cytotoxic T lymphocyte antigen (CTLA) deficient mice started to die between 3rdand 5thweek due to cardiac complications [42,43].Though the pathogenesis behind cardiotoxicity is still poorly understood,some article referred that PD 1 inhibitor produces autoantibodies against cardiac myosin[44].Pembrolizumab (PD 1 inhibitor) causes cardiotoxicity by accumulating excess intracellular calcium,and reduction in cardiomyocyte viability [45].Other possible causes include targeting an antigen shared by the tumor,skeletal muscle,and the heart by T cells,resulting in low selectivity of the enhanced T cell responses between cardiac and skeletal muscle which leads to myocarditis(Fig.3) [41].

    Fig.3.CTLA inhibitor like ipilimumab acts via switching off a negative regulator of T cell activation that prevents antitumor T cell responses,and PDL-1 inhibitor (pembrolizumab) removes a barrier to T cell function once T cells have infiltrated the tumor and its environment.In addition,ipilimumab and nivolumab also enhance T cell responses in cardiac and skeletal muscle,leading to autoimmune cardiotoxicity.Reproduced with permission from [41].Copyright 2017,Cell Press.

    2.2.Cardiotoxic chemotherapeutics

    The anthracycline antibiotics are arguably one of the most active groups of chemotherapeutic agents in oncology.Commonly used anthracycline antibiotics include DOX,daunorubicin,and epirubicin.They have proven activity against a spectrum of malignancies,including lymphoma,gastric cancer,small cell lung cancer,sarcomas,and breast cancer.Anthracycline causes dose dependent heart failure,and myocarditis for instance,DOX causes dose dependent cardiomyopathy where risk of cardiac failure increases linearly from 2.2% to 7% at a dose above 550 mg/m2 [17,18,46].Majority of the patients develop cardiomyopathy within first year of treatment with a mortality rate more than 40% [17].Almost 9.9%of patients treated with daunorubicin experience cardiomyopathy.Trastuzumab and anthracyclines combination treatment found severe (NYHA III–IV) heart failure in 16% of patients.This incidence was much higher than that associated with anthracycline treatment alone [33].In one study 17 out of 172 children treated with daunorubicin showed cardiac complications with 360–1260 mg/m2dose.

    5-FU is a very potent anticancer drug used widely in gastrointestinal cancer.Due to its cardiotoxic effect,now a days,alternative medicines like raltitrexed are considered [47].Some review articles thoroughly discussed about the cardiotoxicity profile of 5-FU [48–50].A study conducted in 1997 among the patients treated with 5-FU reported that 1.9% of patients develops symptomatic cardiac complications [51].It has been observed from a meta-analysis from different clinical trial that cumulative 7.9% patients reported cardiac complications.Among that 44.9% patients reported arrhythmia and 1.9% patients developed ischemic event [52].

    A large variety of cardiotoxic events with manifestations such as heart failure,cardiomyopathy,heart block,myocardial fibrosis and myocarditis was documented with anti-CTLA-4 and anti-PD 1 (immune-checkpoint inhibitor [ICI]) therapy [53].Several studies reported autoimmune myocarditis and heart failure in patients treated with pembrolizumab [53–56].79% (23 out of 30) reported left ventricular dysfunction from ICI with a 27% mortality rate [57].A case report of 2 patients published in 2016 stated that a combination therapy with ipilimumab and nivolumab caused myocarditis where none of the patient had any cardiac risk factors except hypertension [58].However,another study,in patient receiving combination of 3 mg/kg ipilimumab and 1 mg/kg nivolumab,found patients experiencing myocarditis [59].

    Radiation therapy involves damages in the surrounding tissue and causes pericardial disease,restrictive cardiomyopathy,accelerated coronary artery disease,and valvular heart disease [7].Radiation-induced cardiac disease is 10% to 30% by 5 to 10 years post-treatment [60].

    Table 1 summarizes the known cardiovascular side effects of commonly used anticancer drugs [18,30,37,50,61-93]

    Table 1 This table summarize the known side effect of the commonly used anticancer drugs.

    3.Monitoring and screening of cardiotoxicity

    3.1.Common monitoring method and its importance

    An article published in The U.S.Pharmacist [94]stated that cardiotoxicity ranges from reversible,irreversible,acute,chronic and late onset can simply be classified into two groups: reversible and irreversible.A meta-analysis on childhood cancer survivor stated that the childhood cancer survivors are at 15 times higher risk of developing CHF and 7 times higher risk of early death due to cardiovascular complication [95–97].Severity of cardiotoxicity can be determined from the following markers.For example,40%?49% LV ejection fraction (LVEF) indicates moderate cardiotoxicity,whereas,LVD with LVEF ≤40% indicates severe cardiotoxicity [98].Mortality rate of patients with severe cardiotoxicity was 22.9% [98].Therefore,early diagnosis of cardiovascular side effect is crucial to be able to select appropriate therapy.Early diagnosis can decrease the mortality rate,improve quality of life and halt further development of cardiovascular dysfunction.To mitigate these side effects,researchers proposed some monitoring methods like serial endocardial biopsy,serial B-type natriuretic peptide (BNP) and troponin level testing,radionucleotide MUGA or radionucleotide angiography,exercise testing,and echocardiogram.Currently established guideline for screening chemotherapy related cardiotoxicity includes assessment of left ventricular(LV) ejection fraction (EF),LV blood volume,diastolic function,MRI,computed tomography (CT),and positron emission tomography (PET) [99,100].Other monitoring methods that are used in clinic includes endomyocardial biopsy,radionuclide angiocardiography (RNA),molecular imaging,and biochemical markers such as troponin T and B-natriuretic peptide (BNP) [101,102].Here we will discuss the screening and monitoring methods in 4 different sections: (1) Screening based on clinical manifestation,(2)Analysis from cardiotoxic biomarker,(3) Imaging technologies,(4)Others.

    3.2.Physical appearance and clinical manifestation

    Cardiotoxicity that usually occurs are angina,arrythmia,tachycardia,bradycardia,atrial fibrillation,cardiomyopathy,congestive heart failure [103,104].Risk factors for developing various degree of toxicity includes dose of chemotherapy,age,sex,preexisting heart disease,high blood pressure [105].Other preexisting conditions include diabetes,renal disease,electrolyte imbalance,high cholesterol,smoking [106,107].The risk factors should be evaluated before starting the treatment.As,risk and degree of cardiotoxicity is worst with pre-existing condition,the patients should be screened for risk factors and conditions should be treated or modified beforehand [107].

    Unfortunately,the treatment of cardiotoxicity is still symptomatic and physical appearance or changes in physical activity is visible when the cardiac damage is very significant and in late stage.In most of the cases mild and reversible symptoms are not physically appeared.Coincidingly the physical characteristic of patient undergoing cardiotoxicity involves having shortness of breath,chest pain,fluid retention in the legs,stomach distention,dizziness,and heart palpitations.Though in most of the cases anticancer induced cardiotoxicity had no clinical manifestation or remain asymptomatic as subclinical cardiotoxicity,the treatment of cardiotoxicity is symptomatic [107–109].However,caregivers put the patients under continuous monitoring for heart rate and blood pressure when a patient is being treated with cancer chemotherapeutics to observe cardiac function.The sign and symptoms mediated detection methods are often scientifically invalid and nonquantitative.In many cases abnormal sign and symptoms may lead the oncologist to decide on further diagnosis and determine on dosage amount and frequency.

    3.3.Utilizing biomarkers as a read out for cardiotoxicity detection

    According to the National Institutes of Health,biomarkers are defined such that to objectively measure and evaluated as an indicator of normal biological processes,pathogenic,or pharmacologic responses to therapeutic intervention [110].Therefore,biomarkers are determined by their abilities to have relevance to provide information clinically to health officials and validity to support the effectiveness of using biomarkers as a resource to compare the normal to any anomalies [110].Moazeniet al.has reported that there are several specific biomarkers that upregulate due to induction of cardiotoxicity.These circulating biomarkers such as cardiac troponin and natriuretic peptides could be used for detecting and monitoring cardiac health status.On top of these widely reported biomarkers,galectin-3,soluble ST-2 proteins,myeloperoxidase and fibrocytes are being explored to reliably predict the onset of cardiotoxicity early [111].Refer to Table 2 for a list of various biomarkers that can be considered as read-out to monitor cardiotoxicity [112–149].Therefore,it is imperative to understand transcriptomics,proteomics and metabolomics systems in order to understand anthracycline-induced cardiotoxicity [111].miR-208a has been identified as a heart-specific molecule to be used as an indicator for pre-drug induced cardiotoxicity,regulator of cardiac hypertrophy and biomarker implied cardiac miRNAs are abundantly expressed in the myocardium,that has a vital role in heart function and heart pathology [111,150,151].Decreased level of miR-1–3p,miR-122–5p,miR-127–3p,miR-133a-3p,miR-215–5p,miR-455–3p,and miR-499a-5p,and increased miR-34a-5p level was found in doxorubicin induced cardiotoxic mouse model than the healthy control [152].

    Table 2 List of various biomarkers that can be considered as read-out to monitor cardiotoxicity.

    3.4.Using imaging technology for cardiotoxicity detection

    Imaging modalities are the mostly used technique to determine cardiotoxicity [153].Abnormal Electrocardiogram (ECG) is widely used to diagnose acute cardiotoxicity.Visualization of cardiotoxicity for qualitative and quantitative analysis of degree of toxicity play vital role in the medical profession.With modern technology,there are various instruments and techniques to detect and monitor degree of cardiotoxicity.In 2019,a review article by Awadallaet al.has demonstrated various techniques that have been using in clinic or have potential to detect cardiotoxicity.The conventional non-invasive imaging procedures for diagnosis of cardiac dysfunction includes echocardiography,cardiac magnetic resonance (CMR)and multigated acquisition (MUGA) scans [8,154-156].2D echocardiography is the most common and available imaging modality though 3D echocardiography provides better accuracy [157].A study on childhood cancer survivor reported that,children treated with anthracycline,measuring of circulating biomarkers coupled with 3D echocardiography and cardiac MRI is more effective in diagnosing late cardiac event [158].Other accessible imaging technique includes stress echo,myocardial strain imaging [159,160].Myocardial strain imaging is recommended every 6 months after completion of chemotherapy for type 1 cardiotoxic drug and for type 2 cardiotoxic drug every 3 months during the therapy.Singlephoton electron computed tomography (SPECT),Positron emission tomography (PET),Computed tomography (CT) are also useful tools to cardiotoxicity detection [161,162].Research has been going on to detect chemotherapy related cardiotoxicity by non-invasive or minimal invasive imaging.68Ga-Galmydar (a PET imaging tracer)could detect the cardiotoxicity in rat using microPET scanning only after 5 days of injecting a single dose of DOX (15 mg/kg)[163].Other PET tracer used to detect cardiac toxicity includes18F-labeled lipophilic phosphonium cation,18F-fluorodeoxyglucose(FDG) [164–167].A report onin vivostudy demonstrated that18FDHMT (a marker for ROS) PET imaging could detect an elevation in cardiac superoxide production in anthracycline treated rat before decreasing the LV ejection fraction [168].Anthracycline induced cardiotoxicity in mice was also detected by molecular imaging of apoptosis using18F-CP18 (a caspase-3 substrate) [169].An increase uptake of18F-CP18 can be observed by microPET,autoradiography and TUNEL staining.In addition increased FAP expression can be detected in a chemotherapy induced cardiotoxic patient by using Ga-68 fibroblast activation protein inhibitor (FAPI) positron emission tomography (PET)/computed tomography (CT) [170].

    4.Patient management

    4.1.Current clinical guideline and treatment

    Due to the severity and vast majority of the patients receiving chemotherapy,end up developing cardiac complications,a new field “cardio-oncology” is emerging for clinical management.Cardio oncology is a multidisciplinary team consisting of medical oncologist,cardiologist,radiation oncologists,hematologists,and specialized nurse [171,172].This team focused on recognizing the risk factors,diagnosis of cardiotoxicity,determining the stage of toxicity,taking proper management to treat the condition and long term monitoring of the surviving patients,and making guidelines [172–174].A report published from a cardio oncology clinic demonstrate among the patients referred (breast cancer patients receiving trastuzumab and developed cardiotoxicity) to their clinic,>90% of them could finish the treatment successfully with trastuzumab despite having existing cardiotoxicity [175].In 2017 and 2018,American Society of Oncology (ASCO) provided a recommendation and guideline for management of cancer survivors with cardiac dysfunction [8,176].ASCO and ESMO (European Society for Medical Oncology) have their own guideline for managing the patients with chemotherapy induced cardiotoxicity [177,178].A cardio-oncology expert panel from the French Working Group of cardio-oncology analyzed both guidelines to harmonized them[174].However,all the guidelines recommended to manage the situation with a multidisciplinary approach,screening before and after starting a cardiotoxic treatment and taking alternative approach(if available) for the high-risk group.

    Fig.4.The scheme describes the method of monitoring and management of a cancer patient.A cancer patients should first be screened for the risk factor for cardiovascular diseases before starting chemotherapy.If there is any pre-existing risk factor,they should be monitored frequently then other group with the ongoing chemotherapy.During the chemotherapy monitoring (by clinical manifestation,serum analysis for cardiotoxic biomarker,imaging analysis) should be continued.Appropriate management should be taken if the patient diagnosed with cardiotoxicity in the process.The alternative treatment management might also be considered in future for prevention of cardiotoxicity.

    Management for anthracycline and other dose related cardiotoxicity includes careful monitoring (Fig.4) of dose and measurement of systolic function at 6 months after the conclusion of treatment,every year for following 2 or 3 years of post-treatment,and then every 3-to 5-year intervals for lifetime [179].In general,the managements include early detection of anticancer drug induced LVD and treatment.As a treatment for LVD angiotensinconverting enzyme inhibitors (ACE-I) and beta-blocking agents (BB)is recommended to use [180,181].According to the American College of Cardiology and American Heart Association guidelines patients receiving chemotherapy may be considered in the group of stage A HF [182].Use of liposome-encapsulated doxorubicin along with carvedilol,valsartan,dexrazoxane should be considered [168].Patients with HF and cardiomyopathy should be treated according to the established guideline of AHA/ACC in general [183,184].

    4.2.Potential use of antioxidant drug

    Antioxidants collects the free radicals from the body produced by the cells and prevents or reduce the risk of potential damages caused by oxidations.Alone the same line,some antioxidant cardiovascular drugs,such as ACEI (enalapril,captopril,and lisinopril),dexrazoxane,beta blocker (carvedilol,nebivolol) as well as some experimental antioxidant agents such as ranolazine,statins,and phosphodiesterase-5 inhibitors,have shown potential to improve cardiac health insulted by the cardiotoxic drugs [30,185,186].Anticancer drug results in increase production of reactive oxygen species,in other word oxidative stress,within the cardiomyocytes and that lead to cardiac dysfunction.The reactive oxygen species interfere and attack various cellular biomolecules such as lipid,protein and genetic molecules and that resulting in of accelerating tissue damage and cell death.Therefore,antioxidant drugs may have potential to reduce the oxidative stress level by capturing the reactive oxygen species and mitigate the cardiotoxicity of the anticancer drugs.For instance,studies show that carvedilol played vital role in improving the DOX induced mitochondrial cardiotoxicity [185].Dexrazoxane acts as a cardioprotective agent for anthracycline-induced cardiotoxicity by interfering with irondependent redox reactions hence reduces ROS production and inhibits topoisomerase IIβwhich prevents anthracycline binding and DNA double-strand breakage [2,187].A review article by Rodrigoet al.has demonstrated the tole of reactive oxygen species in cardiac damage and how antioxidant vitamins effects on protecting the heart [188].Various studies have reported on the potential cardioprotective effects of vitamin E and C,studies conducted in both pre-clinical and clinical stages [189,190].Vitamin C,an another widely considered antioxidant,has shown potential effects in cardio-protection.However,the plasma concentration of orally administrated vitamin C is as low as 100 μmol/L which is not sufficient to induce enough antioxidant effect.Therefore,an intravenous administration,which can lead to 25–30 mmol/L plasma concentration of vitamin C,is a more preferable route of administration in order for vitamin C to provide enough cardioprotective effects [191].Therefore,we envision that with a proper dose and route of administration antioxidant vitamins can be used as a potential cardioprotective agent while a patient is being treated with cardiotoxic anticancer drug.

    4.3.Other cardioprotective modalities

    Besides antioxidant drugs,there are other therapeutic modalities that have also shown potential as a cardioprotective agents.For instances,cannabidiol,a major chemical component found in a Cannabis sativa plant,protects the heart from DOX-induced cardiomyopathy by modulating mitochondrial function and biogenesis [192].Alone the same line,Liuet al.has reported that visnagin protects heart from DOX-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase studies conducted in zebra fish [193].In the same study,Visnagin treatment has shown to improve cardiac contractibility in doxorubicin treated mice.Use of sporopollenin encapsulated imatinib showed controlled release which was 65% within 24 h compared to the control (only imatinib).Only Imatinib released fast and it took only 1 h to release the whole formulation [194].Another study shows PEG polyaspartate bound Epirubicine micelle have more antitumor effects also then only Epirubicin in hepatocellular cancer mice model cardiotoxicity of epirubicin.It also reduced the cardiotoxic effect of Epirubicine [195].Transplantation of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC–CMs) can also reduce the DOX-induced cardiotoxicity [196].

    4.4.Targeted drug delivery

    Targeted drug delivery to approach as an attempt to reduce cardiotoxicity is still in research.Several of recent studies have reported that targeted delivery of anticancer medications has potential to reduce cardiotoxicity.Degree of cardiotoxicities are mostly dose dependent for most of chemotherapeutic drugs.Disease specific targeted delivery system results higher accumulation of drug within the targeted side of the body and even specific region of the organ [197,198].The higher drug accumulation with the targeted organ also facilitated reduction of non-specific wanted biodistribution and toxicity related to that.For instances,liposomal encapsulation [199–202],mitochondrial delivery [203–206],chemical modification [206],nano-particle encapsulation [207–210],red blood cell loaded [211],and exosome mediated delivery [212]approaches are being considered to increase the therapeutic effect as well as improve cardiac protection.Liposomal vehicle mediated anticancer delivery systems have also been found effective in cardiac protection [213–215].Various preclinical and clinical studies showed that liposomes can predominantly enhance drug accumulate in tumor tissue thus provide improved anticancer activity [216].Studies shows that,liposome sizes ranges between 100 and 200 nm in diameter has better extravasate and accumulate in to tumor site thus better anticancer effect [216].In recent years,several liposomal drug formulation has been clinically approved for anticancer treatment [217].Data from liposome-entrapped Adriamycin(ADM) treated mice model indicated that the levels of ADM were increased several fold in the liver and the spleen with diminished accumulation in heart [218].In another report,Liposomal based-Paclitaxel formulation in metastatic lymphoma mice model showed significantly reduced systemic side effect including cardiac toxicity[219].Alone the same line,co-delivery of liposome of berberine(BER) and DOX significantly inhibited tumor growth in 4T1 murine mammary carcinoma model (P <0.05) and completely overcame the myocardial rupture toxicity compared to free drug [220].PEGylated liposomal DOX showed improved cardiac biopsy in Kaposi Sarcoma patients 0.3vs.3.0 [221].

    A very recent study by Wallaceet al.has demonstrated that mitochondrial targeted delivery of cancer therapeutics can improve specificity for cancer cells by acting on targets that only exist in mitochondria of cancer cells thus reduced off targeting mediated side effect [222].A class of HSP90 inhibitors induce rapid mitochondrial membrane permeabilization and cell death in cancer cells while leaving normal cells unaffected [223].Mitochondrial targeted delivery of DOX prevents the nuclear DNA damage and improves myocardial health in H9C2 cell line [203,224].Mitochondrial targeted delivery of resveratrol in DOX-induced cardiomyopathic cell activates cardiac progenitor cells and increase the longevity of mice [225].Another study reported that mitochondrial targeted MitoQ10 significantly reduces the systolic blood pressure (25 mmHg over 8 weeks) and improves cardiac circulation[226].Chemical modification of the parent molecule has also potential in reducing non-specific localization mediated toxicity.For instances,modification of DOX (analogs) and targeted delivery of anthracyclines delivered specifically to the tumor tissue reduces the cardiac side effects [227].

    A generation 5 (G5) poly(amidoamine) dendrimers based nanoparticle mediated intertumoral delivery of DOX into hepatic cancer cell has shown significantly reduction the toxic effect of DOX without compromising therapeutic efficacy [228].Applications of human serum albumin conjugated DOX showed accelerate tumor inhibition efficacy;as well as reduced cardiotoxicity[229–231]observed by cardiac imaging and other cardiac biomarkers such as serum creatine kinase-MB,lactate dehydrogenase,superoxide dismutase,and malonaldehyde [232].PLGA loaded imatinib nanoparticle showed great efficacy bothin vivoandin vitrowithout any significant cardiac symptom [233].Resveratrol solid lipid nanoparticles improves DOX induced cardiomyopathy [234].Study also showed that superparamagnetic iron oxide nanoparticles coated with DOX conjugated heparin had more conventional toxicity,antitumor efficacy and less cardiac toxic effect bothin vivoandin vitrostudy [235].Similar studies was done with other anticancer drug also like docetaxel [236],and with different coating like dextran [237],chitosan [238].

    These theragnostic agents,a combination of imaging and therapeutic modalities,could be used for noninvasive early detection as well as treatment of cardiotoxicity.Other nanoparticles like silica [239],gold [240],PLGA [241]were used,in regard to increase therapeutic effect and reduce potential side effect.Colloidal mesoporous silica nanoparticles (MSNs) functionalized with DOX,and incorporated into Pluronic F127 hydrogels for prolonged release generated great anti-tumor effect in rat with reduction in cardiac side effect [242].Other chemicals has been used with MSNs like galactosylated chitosan [243],succinylatedε-polylysine [244],MUC1 aptamer conjugation [245–247].

    4.5.Advancement in cardiotoxic drug delivery

    Most of the anticancer drugs,such as DOX,that commonly target caspase 3 and caspase 7 to trigger apoptosis,induce [248].At the same time,using a certain concentration,especially for DOX at 15 mg/kg may cause acute cardiotoxicity [249,250].Studies suggest that polymeric micelles derived from resveratrol (RES) and quercetin (QUE) can reduce cardiotoxicity bothin vitroandin vivo.On this study they produced DOX induced cardiotoxicity on ovarian cancer cell line and found that the delivery of DOX with a combination of RES and QUE in Pluronic? F127 micelles increase the efficacy of DOX [250].

    It has been found in the study that overexpression of miR-132 and miR-212 induce cardiomyocyte hypertrophy [251].Result from another study stated that overexpression of miR132/212 inhibited the doxorubicin-induced atrophy on their rat model cardiomyocytes [252].Various drug deliveryvehicles including coencapsulated ICGOx@IO (iron oxide (IO,indocyanine green (ICG)and glucose oxidase (GOx)) with doxorubicin (DOX),and an EGCG((-)-epigallocatechin-3-gallate) loaded PLGA have been found as comparatively safer approaches that has significantly less cardiotoxicity.On top of that near infrared laser mediated dug release and tissue dissociation at the tumor site has been shown to complete ablation of tumor in mice including significantly less cardiotoxicity [253].Near infrared laser mediated release of drug using ultrasound targeted microbubble destruction (UTMD) assisted exosomal delivery of miR21 could also decrease the cardiac cell death and restore the function in DOX induced cardiotoxic mice model [212].In another study,PHPMA35-b-PDPA75 a pH responsive polymerase based delivery of DOX has been shown to have a reduced cardiac side effect while having full potential of treating lymphoma in mice [254].Along the same line,codelivery of formaldehyde and DOX,calycosin-PEG-PPG-PEG copolymer nanomicelles mediated DOX delivery has also been shown to have the antitumor efficacy with less cardiotoxic effect [255,256].Codelivery of DOX with digoxin also showed to improve cardiotoxicity [257].To conclude this segment,ongoing projects are seeking new avenues to treat the oxidative damages that DOX causes and approaching it by either polymeric micelles delivery or targeting expression to inhibit oxidative damage.Therefore,it may be possible to apply anti-cancer treatment at their full potential to patients with less cardiotoxic effects.

    5.Conclusion and perspectives

    Recent progress in anticancer drug development has significantly improved cancer treatment and management in clinic that has resulted saving millions of lives.However,anticancer therapy induced cardiotoxicity is responsible for many cardiac morbidity and mortality.To reduce the cardiotoxic effect of anticancer drug we need a holistic approach.These includes identifying cardiotoxic drug,understanding mechanism of action in tumor cell and cardiac cell,early diagnosis of toxicity by utilizing conventional and newer biomarkers and technologies,and managing the toxicity clinically.Alternative medicine and modified drug delivery approach may consider as an emerging field for preventing cardiotoxicity.

    Though pathogenesis of anticancer drugs is not clearly and completely understood,rationale designing of further research is needed to better understand molecule specific mechanism of cardiotoxicity and associated biomarkers.Further understanding of structure of circulating biomarkers,if any,will guide us in developing imaging technologies.Moving forward,structural modification of the parent drug can potentially contribute to reduce side-effects but there is a high risk of compromising their efficacy in term of therapeutic profile [258,259].Nanotechnology based formulation and drug delivery approach has shown significant progress over the last decades and many of formulations,for instances ABRAXANE? a formulation of paclitaxel and albumin show reduced side effects compared to that of the free form of paclitaxel [260–262].Alone the same line,various polymeric vehicles such micelles,and liposome also have shown potential for cellular and organ specific drug delivery feasibility as well as facilitate less interaction between the biological molecules and drug molecules.Such strategies may have effectiveness in reducing the unwanted effect of the drug molecules without compromising their therapeutic efficacy.Various biocompatible polymeric materials such as polyethylene glycol,and poly(D,L-lactic acid) have great potential of carrying adequate amount of drug payload from site of administration to the site of action [263–266]Such carrier molecule can prevent any possible interaction of the drug molecules with the biomolecules during the systemic circulation,hence reduce toxicity of the anticancer drug.

    In addition to the developing formulation to reduce non-specific localization mediated toxicity,a feasible monitoring modality that can facilitate real-time and quantitively detection of cardiotoxicity can improve cancer patient management in clinic.As demonstrated earlier,though there are several cardiotoxicity monitoring modalities available and used in clinic but none of the modalities are good enough to detect the degree of toxicity at early stage and with a quantitative manner.Therefore,development of a more feasible and sensitive tools that can detect the upregulated circulatory proteins and quantify the cardiotoxicity biomarker can be used for real-time and at early-stage toxicity monitoring.With development and implementation of such detection technology,a cancer patient management can be improved,and irreversible cardiotoxicity can be mitigated.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    Md Nurunnabi acknowledges the research grant supported by Lizanell and Colbert Coldwell Foundation.The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding this work,through their research group (No.RG-1435–017).

    午夜免费观看性视频| 一区在线观看完整版| 精品亚洲成a人片在线观看| 伊人久久国产一区二区| 日日啪夜夜爽| 欧美成人精品欧美一级黄| 亚洲国产色片| 成人漫画全彩无遮挡| 菩萨蛮人人尽说江南好唐韦庄| 亚洲av欧美aⅴ国产| 黑人欧美特级aaaaaa片| 国产精品一国产av| 亚洲美女黄色视频免费看| 91午夜精品亚洲一区二区三区| 国产永久视频网站| 99国产综合亚洲精品| 欧美日韩一区二区视频在线观看视频在线| 熟女电影av网| 制服丝袜香蕉在线| 亚洲激情五月婷婷啪啪| 午夜av观看不卡| 欧美丝袜亚洲另类| 亚洲成色77777| 精品国产露脸久久av麻豆| 蜜臀久久99精品久久宅男| 九九爱精品视频在线观看| 色婷婷av一区二区三区视频| 国产极品粉嫩免费观看在线| 18禁在线无遮挡免费观看视频| 在线天堂中文资源库| 精品亚洲成国产av| 日韩免费高清中文字幕av| 国产一区二区三区av在线| 欧美+日韩+精品| 在现免费观看毛片| 日本wwww免费看| 亚洲成人一二三区av| 最新中文字幕久久久久| 亚洲精品美女久久av网站| 曰老女人黄片| 久久久久久伊人网av| 国产av精品麻豆| 国产日韩欧美在线精品| 有码 亚洲区| 国产精品久久久久久精品古装| 国产亚洲欧美精品永久| 成人免费观看视频高清| av在线app专区| 日本黄色日本黄色录像| 欧美日韩精品成人综合77777| 国产视频首页在线观看| 男女边摸边吃奶| 欧美亚洲日本最大视频资源| 日本wwww免费看| 日韩av不卡免费在线播放| 久久久欧美国产精品| 亚洲四区av| 在线观看免费日韩欧美大片| 最后的刺客免费高清国语| 亚洲经典国产精华液单| 飞空精品影院首页| 国产精品久久久久久av不卡| 亚洲伊人久久精品综合| 久久精品久久精品一区二区三区| 晚上一个人看的免费电影| kizo精华| 欧美精品一区二区免费开放| 亚洲 欧美一区二区三区| 青春草国产在线视频| 午夜福利乱码中文字幕| 久久久亚洲精品成人影院| 五月玫瑰六月丁香| a级毛片黄视频| 国产精品久久久av美女十八| 亚洲一码二码三码区别大吗| 亚洲欧洲日产国产| 在线免费观看不下载黄p国产| 夜夜爽夜夜爽视频| 中文天堂在线官网| √禁漫天堂资源中文www| 99久久精品国产国产毛片| 乱人伦中国视频| 亚洲中文av在线| 男人操女人黄网站| 日日爽夜夜爽网站| 如日韩欧美国产精品一区二区三区| 婷婷色综合www| 日韩中字成人| 亚洲国产精品999| 久久午夜福利片| 在线观看三级黄色| 日韩不卡一区二区三区视频在线| av网站免费在线观看视频| 好男人视频免费观看在线| 狠狠婷婷综合久久久久久88av| 美国免费a级毛片| 女性被躁到高潮视频| 免费播放大片免费观看视频在线观看| 精品视频人人做人人爽| 久久人妻熟女aⅴ| 七月丁香在线播放| 中文字幕精品免费在线观看视频 | 制服人妻中文乱码| 激情视频va一区二区三区| kizo精华| 最黄视频免费看| 亚洲欧美日韩卡通动漫| 97在线人人人人妻| 人成视频在线观看免费观看| 中文字幕最新亚洲高清| 国产精品久久久久久久久免| 久久久久久久久久人人人人人人| av又黄又爽大尺度在线免费看| 亚洲综合精品二区| 久久精品熟女亚洲av麻豆精品| 国产免费福利视频在线观看| 精品一区在线观看国产| 婷婷成人精品国产| 亚洲人成77777在线视频| 少妇人妻久久综合中文| 99久国产av精品国产电影| 亚洲欧美色中文字幕在线| 国产成人精品久久久久久| 大码成人一级视频| 欧美成人午夜精品| 91精品三级在线观看| 五月伊人婷婷丁香| 一本大道久久a久久精品| 又黄又爽又刺激的免费视频.| 国产有黄有色有爽视频| 国产精品免费大片| 国产精品久久久久久精品古装| 不卡视频在线观看欧美| 国产成人91sexporn| 午夜91福利影院| 新久久久久国产一级毛片| 最近中文字幕2019免费版| av免费在线看不卡| 国产片特级美女逼逼视频| 亚洲精品久久成人aⅴ小说| 中文天堂在线官网| 看免费av毛片| 国产亚洲av片在线观看秒播厂| 99视频精品全部免费 在线| 国产精品人妻久久久影院| 五月天丁香电影| 两个人免费观看高清视频| 日韩av在线免费看完整版不卡| 伦理电影免费视频| 男人舔女人的私密视频| 日本-黄色视频高清免费观看| 亚洲av福利一区| 日韩 亚洲 欧美在线| 亚洲欧美成人精品一区二区| 精品一区二区免费观看| 久久久久精品性色| 精品少妇黑人巨大在线播放| 日韩制服骚丝袜av| 午夜激情av网站| 日韩成人伦理影院| 极品人妻少妇av视频| 免费日韩欧美在线观看| 尾随美女入室| 成人国产av品久久久| 老司机亚洲免费影院| 久久国产精品大桥未久av| 午夜福利视频在线观看免费| 亚洲成人一二三区av| 国语对白做爰xxxⅹ性视频网站| 有码 亚洲区| 少妇人妻久久综合中文| 街头女战士在线观看网站| 丝袜人妻中文字幕| 伊人亚洲综合成人网| 中文字幕另类日韩欧美亚洲嫩草| 亚洲久久久国产精品| 蜜桃在线观看..| 亚洲美女黄色视频免费看| 久久 成人 亚洲| av线在线观看网站| 一级片免费观看大全| 亚洲av电影在线观看一区二区三区| 亚洲精品中文字幕在线视频| 免费观看av网站的网址| 精品第一国产精品| 国产精品久久久av美女十八| 男人操女人黄网站| 欧美日韩国产mv在线观看视频| 99热全是精品| 性高湖久久久久久久久免费观看| 日韩大片免费观看网站| 天堂俺去俺来也www色官网| 国产亚洲精品第一综合不卡 | 久久综合国产亚洲精品| 丝袜脚勾引网站| 另类亚洲欧美激情| av片东京热男人的天堂| 欧美成人午夜精品| 在线天堂最新版资源| 国产男女内射视频| 黑人巨大精品欧美一区二区蜜桃 | 在线 av 中文字幕| 岛国毛片在线播放| 国产亚洲午夜精品一区二区久久| 高清在线视频一区二区三区| 国产成人精品无人区| 色吧在线观看| 五月开心婷婷网| 久久久久国产网址| 波多野结衣一区麻豆| 国产精品免费大片| 日韩免费高清中文字幕av| 国产无遮挡羞羞视频在线观看| 久久狼人影院| 久久久久久久久久人人人人人人| av福利片在线| xxxhd国产人妻xxx| a 毛片基地| 婷婷色av中文字幕| 欧美97在线视频| 国产精品久久久久久久电影| 搡女人真爽免费视频火全软件| 久久青草综合色| 激情视频va一区二区三区| 亚洲国产看品久久| 永久网站在线| 日韩精品有码人妻一区| 中文字幕精品免费在线观看视频 | 精品久久久久久电影网| 超碰97精品在线观看| 久久国产精品大桥未久av| 国产精品欧美亚洲77777| 亚洲国产成人一精品久久久| 男女边摸边吃奶| 9191精品国产免费久久| 亚洲在久久综合| 久久久久视频综合| 99久久人妻综合| 男女边摸边吃奶| 9191精品国产免费久久| 国产一区二区三区综合在线观看 | 亚洲,欧美精品.| 十分钟在线观看高清视频www| 99热全是精品| 美女大奶头黄色视频| 少妇猛男粗大的猛烈进出视频| 久久精品熟女亚洲av麻豆精品| 国产国语露脸激情在线看| 午夜激情av网站| 波野结衣二区三区在线| 日韩成人av中文字幕在线观看| av在线老鸭窝| 日韩不卡一区二区三区视频在线| 亚洲精品中文字幕在线视频| 亚洲精品久久久久久婷婷小说| 国语对白做爰xxxⅹ性视频网站| 欧美人与善性xxx| 午夜激情久久久久久久| 国产在线一区二区三区精| 汤姆久久久久久久影院中文字幕| av女优亚洲男人天堂| 亚洲经典国产精华液单| 黄色怎么调成土黄色| h视频一区二区三区| 亚洲欧美成人综合另类久久久| 国产精品嫩草影院av在线观看| 亚洲在久久综合| 自拍欧美九色日韩亚洲蝌蚪91| 国产精品蜜桃在线观看| 最新的欧美精品一区二区| 国产亚洲精品久久久com| 久久狼人影院| 国产黄频视频在线观看| 中文乱码字字幕精品一区二区三区| 久久这里有精品视频免费| 日韩av不卡免费在线播放| 五月伊人婷婷丁香| 视频在线观看一区二区三区| 人人妻人人澡人人爽人人夜夜| 日韩av在线免费看完整版不卡| 亚洲综合色惰| 久久久久久久精品精品| 飞空精品影院首页| 国产白丝娇喘喷水9色精品| 国产麻豆69| 免费大片18禁| 熟妇人妻不卡中文字幕| 日本-黄色视频高清免费观看| 91久久精品国产一区二区三区| 午夜福利影视在线免费观看| 免费黄频网站在线观看国产| 精品福利永久在线观看| 男女边吃奶边做爰视频| 久久人人爽人人片av| 午夜福利,免费看| 99热国产这里只有精品6| 18禁在线无遮挡免费观看视频| 精品亚洲乱码少妇综合久久| 国产免费一级a男人的天堂| 黄片无遮挡物在线观看| 亚洲精品久久午夜乱码| 国产深夜福利视频在线观看| 制服丝袜香蕉在线| 黑人猛操日本美女一级片| 亚洲精品第二区| 午夜福利,免费看| 久久这里只有精品19| 曰老女人黄片| 97超碰精品成人国产| 国产精品成人在线| 国产日韩一区二区三区精品不卡| 在线 av 中文字幕| 久热这里只有精品99| 久久久久久久久久久久大奶| 9色porny在线观看| 久久99热6这里只有精品| 国产在线免费精品| 国产精品国产三级国产av玫瑰| 日本欧美国产在线视频| 成人午夜精彩视频在线观看| 在线观看免费日韩欧美大片| 国产免费视频播放在线视频| 一级爰片在线观看| 国产精品 国内视频| 国产综合精华液| 伊人久久国产一区二区| 中文字幕另类日韩欧美亚洲嫩草| 多毛熟女@视频| 另类精品久久| 波野结衣二区三区在线| 97在线视频观看| 中文字幕亚洲精品专区| 狠狠婷婷综合久久久久久88av| 久久影院123| 91成人精品电影| 色网站视频免费| 丝袜脚勾引网站| 人人妻人人澡人人爽人人夜夜| 一级a做视频免费观看| 国产成人欧美| 亚洲中文av在线| 青春草亚洲视频在线观看| 天天躁夜夜躁狠狠躁躁| 日本黄大片高清| www.熟女人妻精品国产 | 少妇高潮的动态图| 一边亲一边摸免费视频| 九九爱精品视频在线观看| av网站免费在线观看视频| 天美传媒精品一区二区| 国产乱来视频区| 黄色配什么色好看| 日日撸夜夜添| 国产69精品久久久久777片| 日本-黄色视频高清免费观看| 中文字幕av电影在线播放| 久久这里有精品视频免费| 日韩中字成人| av女优亚洲男人天堂| 日韩,欧美,国产一区二区三区| 亚洲内射少妇av| 韩国精品一区二区三区 | 国产69精品久久久久777片| 97精品久久久久久久久久精品| 亚洲欧美清纯卡通| 亚洲精品中文字幕在线视频| 亚洲丝袜综合中文字幕| 免费高清在线观看日韩| 免费高清在线观看视频在线观看| 国产精品国产三级国产av玫瑰| 久久人人爽av亚洲精品天堂| av不卡在线播放| 自线自在国产av| av有码第一页| 欧美精品一区二区免费开放| 国产极品粉嫩免费观看在线| 亚洲国产精品国产精品| 亚洲精品一二三| 国产精品.久久久| 制服诱惑二区| 伦理电影免费视频| 成年av动漫网址| 亚洲激情五月婷婷啪啪| 91在线精品国自产拍蜜月| 国产高清三级在线| 免费高清在线观看视频在线观看| 少妇熟女欧美另类| 欧美日韩视频精品一区| 中文字幕亚洲精品专区| www.色视频.com| 丁香六月天网| 国产精品人妻久久久影院| 精品一区二区三卡| 狂野欧美激情性xxxx在线观看| 欧美老熟妇乱子伦牲交| av在线播放精品| 看十八女毛片水多多多| 午夜91福利影院| 你懂的网址亚洲精品在线观看| 国产亚洲精品久久久com| 满18在线观看网站| 国产精品99久久99久久久不卡 | 两个人免费观看高清视频| 91久久精品国产一区二区三区| 欧美老熟妇乱子伦牲交| 免费观看无遮挡的男女| 老司机影院毛片| 成人无遮挡网站| 99视频精品全部免费 在线| 大香蕉97超碰在线| 免费观看在线日韩| 国产黄色视频一区二区在线观看| 黄片无遮挡物在线观看| 亚洲美女搞黄在线观看| 一本色道久久久久久精品综合| 精品一区二区三卡| 国产高清国产精品国产三级| 在线天堂中文资源库| 国产成人免费无遮挡视频| 国产男女超爽视频在线观看| 中文乱码字字幕精品一区二区三区| a级毛片在线看网站| 亚洲五月色婷婷综合| 国产精品国产三级专区第一集| 亚洲av综合色区一区| 又大又黄又爽视频免费| 午夜福利视频在线观看免费| 多毛熟女@视频| 尾随美女入室| 男男h啪啪无遮挡| 在线天堂最新版资源| a级毛片黄视频| 91午夜精品亚洲一区二区三区| 国产69精品久久久久777片| 少妇被粗大猛烈的视频| 国产色爽女视频免费观看| 又粗又硬又长又爽又黄的视频| 国产午夜精品一二区理论片| av在线播放精品| 大陆偷拍与自拍| 国产亚洲精品久久久com| 母亲3免费完整高清在线观看 | 男人舔女人的私密视频| 亚洲精品色激情综合| h视频一区二区三区| 丰满迷人的少妇在线观看| 日韩,欧美,国产一区二区三区| 久久午夜福利片| 亚洲第一区二区三区不卡| 免费观看性生交大片5| 亚洲成av片中文字幕在线观看 | 下体分泌物呈黄色| 亚洲,欧美,日韩| 欧美精品国产亚洲| 高清在线视频一区二区三区| 精品国产乱码久久久久久小说| 99热全是精品| 伊人亚洲综合成人网| 久久久久网色| 国产在线免费精品| 日韩av不卡免费在线播放| 中文字幕人妻熟女乱码| 亚洲国产欧美日韩在线播放| 国产精品无大码| a级毛色黄片| 欧美精品一区二区大全| 亚洲国产色片| 免费女性裸体啪啪无遮挡网站| 国产精品熟女久久久久浪| 国产不卡av网站在线观看| 人成视频在线观看免费观看| 97人妻天天添夜夜摸| 久久精品人人爽人人爽视色| 亚洲高清免费不卡视频| 日韩熟女老妇一区二区性免费视频| 美女福利国产在线| 成人免费观看视频高清| 久久韩国三级中文字幕| 免费av不卡在线播放| 免费观看无遮挡的男女| 免费大片黄手机在线观看| 嫩草影院入口| 大香蕉久久网| videossex国产| 久久久久久久久久成人| 欧美日韩视频高清一区二区三区二| 亚洲精品美女久久av网站| 精品少妇久久久久久888优播| www.av在线官网国产| 精品少妇内射三级| 久久国产精品大桥未久av| 欧美人与性动交α欧美软件 | 97在线视频观看| kizo精华| 亚洲情色 制服丝袜| 18禁国产床啪视频网站| 精品午夜福利在线看| 精品亚洲乱码少妇综合久久| 日韩三级伦理在线观看| 日本欧美视频一区| 成人国产av品久久久| 日韩精品免费视频一区二区三区 | 成人二区视频| 草草在线视频免费看| 91成人精品电影| 少妇的丰满在线观看| 精品国产一区二区三区四区第35| 久久久国产一区二区| 另类亚洲欧美激情| 综合色丁香网| 岛国毛片在线播放| 亚洲婷婷狠狠爱综合网| 亚洲精品日韩在线中文字幕| 中文字幕精品免费在线观看视频 | 成人无遮挡网站| 制服丝袜香蕉在线| av女优亚洲男人天堂| 18在线观看网站| 我要看黄色一级片免费的| 黑丝袜美女国产一区| 国精品久久久久久国模美| 成人免费观看视频高清| 我要看黄色一级片免费的| 男女啪啪激烈高潮av片| 另类精品久久| 午夜福利网站1000一区二区三区| a级毛片黄视频| 91午夜精品亚洲一区二区三区| 免费看av在线观看网站| 搡女人真爽免费视频火全软件| 国产色爽女视频免费观看| 一级片'在线观看视频| 巨乳人妻的诱惑在线观看| 国产国语露脸激情在线看| 性色av一级| 国产一区二区在线观看日韩| 美女视频免费永久观看网站| 成人国产麻豆网| av在线app专区| 亚洲欧洲国产日韩| 丰满饥渴人妻一区二区三| 69精品国产乱码久久久| 18禁观看日本| 成人手机av| 99热全是精品| 午夜av观看不卡| 亚洲精品国产av蜜桃| 国产极品粉嫩免费观看在线| 乱码一卡2卡4卡精品| 美女国产视频在线观看| 国产高清三级在线| 久久久国产一区二区| 赤兔流量卡办理| 天美传媒精品一区二区| 久久鲁丝午夜福利片| 高清不卡的av网站| 插逼视频在线观看| 亚洲人与动物交配视频| 制服诱惑二区| 男女午夜视频在线观看 | 在线观看一区二区三区激情| 国产国拍精品亚洲av在线观看| 国产日韩欧美在线精品| 久久人人爽人人爽人人片va| 久热这里只有精品99| 欧美日韩视频高清一区二区三区二| 国产成人精品在线电影| 老司机影院成人| 汤姆久久久久久久影院中文字幕| 国产欧美日韩一区二区三区在线| 久久国产亚洲av麻豆专区| 国产成人精品在线电影| 老司机影院成人| 日韩av在线免费看完整版不卡| 亚洲欧美一区二区三区国产| 这个男人来自地球电影免费观看 | 亚洲成人av在线免费| 99久国产av精品国产电影| 欧美精品人与动牲交sv欧美| 激情视频va一区二区三区| 免费播放大片免费观看视频在线观看| 精品99又大又爽又粗少妇毛片| 桃花免费在线播放| 日韩欧美一区视频在线观看| 观看美女的网站| 国产有黄有色有爽视频| 51国产日韩欧美| 久久精品国产自在天天线| 国产又爽黄色视频| 视频中文字幕在线观看| 美女脱内裤让男人舔精品视频| 亚洲精品日本国产第一区| 黄片无遮挡物在线观看| 国产亚洲av片在线观看秒播厂| 夫妻午夜视频| 国产一区二区三区综合在线观看 | 成人毛片60女人毛片免费| 热re99久久精品国产66热6| 日本vs欧美在线观看视频| 久久毛片免费看一区二区三区| 美女福利国产在线| 天天躁夜夜躁狠狠久久av| 亚洲国产欧美日韩在线播放| 日韩中文字幕视频在线看片| 久久久久久久久久成人| 高清欧美精品videossex| av播播在线观看一区| 亚洲精品一区蜜桃| 黑人猛操日本美女一级片| 欧美精品高潮呻吟av久久| 男女边吃奶边做爰视频| 乱码一卡2卡4卡精品| 中国国产av一级| 精品国产一区二区三区久久久樱花| 秋霞在线观看毛片|